Manipal Health Enterprises Ltd Q1 FY2027 Concall Summary

Key Takeaways

• Volume-led quarter, margin dip explained: Ex-Sahyadri EBITDA margin fell to 25% (from 26.5% YoY), but 0.6% of that was a one-off prior-year benefit and the rest is greenfield ramp costs, not operational deterioration.
• Sahyadri integration is delivering early: Revenue grew 13%+ YoY, EBITDA grew 19–20% YoY, and margin reached 17.5%, driven by clinician interoperability, operating efficiencies, and ARPOB improvement.
• Greenfields are ramping ahead of plan: Two Bengaluru greenfields broke even within months and hit 13% EBITDA margin in Q1; their upward trajectory over the next year-plus is expected to pull up the composite portfolio margin.
• Capex front-loaded, balance sheet reset: ₹900 crores spent in Q1 alone toward a ~₹4,000 crores, 3,000-bed expansion plan over 3–4 years; post-IPO net debt to EBITDA drops to 0.9x.
• What to watch next quarter: Sahyadri margin progression as the integration playbook unfolds, the pace of greenfield margin ramp-up, and whether the East region's government scheme transition closes without disruption.

Sahyadri Integration & Performance

• Revenue and margin lift: Sahyadri revenue grew 13%+ YoY and EBITDA grew 19–20% YoY, with margin reaching almost 17.5% in Q1, a significant step-up from the acquired base.
• ARPOB and occupancy gains: ARPOB grew 15% and occupancy reached 63%, while ALOS reduced by 8% to 2.8 days through operating efficiencies, even as case complexity increased.
• Integration playbook in motion: A regional HR structure is in place, 58 clinicians are moving across both brands, digital penetration has started at 22–23% of revenue, and infrastructure upgrades to Manipal systems are underway.
• CONGO mix focus: Sahyadri's CONGO contribution is similar to Manipal's network, but Manipal holds an advantage in case complexity; that playbook is now being applied to Sahyadri to positively impact ARPOB and other financial parameters.
• Brand rechristening timeline: Full rechristening into Manipal is being decided on dates, typically 14–16 months from integration day; the "A Network of Manipal Hospitals" element has already been introduced into the Sahyadri logo.
• Expansion underway within Sahyadri: Deccan Gymkhana is adding an entire tower, Hadapsar is adding beds, a greenfield has started in Wakad (North Pune), Nashik added oncology capacity, and oncology capabilities are being introduced at Ahilya Nagar.

Karthik Rajagopal: "The entire piece is we follow a certain playbook when it comes to looking at acquisitions, you know, and how we look at the integration. So the whole process takes about 16 to 18 months. But your question on when it will get to, you know, the EBITDA for what the network is doing, that obviously is sometime away."

Margin Composition & Bridge

• Ex-Sahyadri margin walk: Q1 margin fell from 26.5% to 25% YoY, a 1.5 percentage point dip. Of that, 0.6% was a one-off material cost benefit in the base quarter from a pre-acquisition Medica contract renegotiation. The remaining 0.9% was driven by greenfield doctor costs (~0.5% network impact) and slower scheme patient collections in Q1.
• Greenfield ramp trajectory: Kanakapura broke even at EBITDA in its fifth month and Yelahanka in its second month, both ahead of expectations; Q1 greenfield EBITDA margin stood at 13%. As they trend up over the next year to year-and-a-half, they will pull up the composite portfolio margin.
• Portfolio aspiration, not guidance: Management pointed to hospitals in the network already at 30–32% margin and stated it would directionally work toward pushing the entire network portfolio to those levels, but declined to guide a specific number or timeline.
• Volume-led philosophy: Growth was driven by volumes, which management views as the sustainable option for care delivery, rather than price-led growth. High-acuity specialties, CONGO-R growth, and ARPOB improvement all contributed.

Dilip Jose: "So therefore, the dip between last year to this year, Shyam, is not something which we are really concerned about. It is not a dip in terms of any operational issues. It is not a dip which is to our mind as a sustainable kind of a situation. These are two one-offs."

Bed Expansion & Capex Plan

• Three-year expansion blueprint: The company plans to add 3,000 beds over the next 3–4 years, spending ~₹4,000 crores of capex, with almost ₹2,000 crores earmarked for the current year and ₹900 crores already spent in Q1.
• Recent and imminent additions: Nashik brownfield expansion commissioned 103 beds with a new linear accelerator and PET-CT (total licensed capacity now 307 beds). The 50th hospital launched in July in Electronic City, Bangalore, adding ~300 beds, taking Bangalore licensed capacity to nearly 3,000 beds.
• Kinder Hospital acquisition: The transaction to acquire the 100-bed women-and-children facility in Whitefield, Bangalore, includes land and building with no rental. The asset will be temporarily closed for renovation and remodelled into a multispecialty facility (excluding transplants and radiation oncology), an 8- to 9-month project that could come on stream in FY27 if accelerated. Conditions precedent are expected to be fulfilled in the next 60 days.
• Pipeline beyond FY27: Raipur greenfield is expected to commission in Q4 FY27; Ahilya Nagar will add close to 80 beds in FY28; Juhu (Mumbai) is slated for commissioning in 2029; Wakad (Pune) greenfield is also in the pipeline.
• Balance sheet capacity: Post-IPO, net debt to EBITDA drops to 0.9x at Q1 levels. Management expressed comfort with 1.5x to 2x leverage and willingness to go higher only for an unmissable opportunity. IPO funds have been received and the debt repayment trigger has been initiated, to be executed in Q2.

Regional & Specialty Dynamics

• East region momentum: AMRI grew 17% YoY and Medica grew 15% YoY, with the East region overall growing 17% top line. Cash and TPA business grew 22% while government business was flat due to a scheme transition from the current scheme to a national scheme, which management expects to close shortly.
• Centres of Excellence driving acuity: Six high-acuity specialties (Cardiac Sciences, Oncology, Neurology, Gastroenterology, Orthopaedics, Renal Sciences) contributed about 65% of revenue, with IP revenues across these growing 45% in Q1 of FY27.
• Oncology mix shift: Oncology's proportion in the network mix moved from 10.8% last year to 12.2%, supported by significant capacity additions in Bangalore via three greenfields commissioned in the last 12 months, all with comprehensive oncology facilities.
• ALOS reduction mechanics: ALOS was brought down from ~4.2–4.3 historically by first removing administrative inefficiencies, then reducing discharge turnaround time via planned discharges and internal process improvements. Government payer mix (~14%) tends to have higher ALOS; international patients remain only ~3% of revenue.
• Expansion geography: Management expressed interest in Kerala as and when an opportunity arises, further expansion in NCR, and looking at Hyderabad for inorganic opportunities.

Karthik Rajagopal: "We don't want anybody to actually go ahead and spend more time in the hospital as a patient, because that's not good for them. They can recuperate much better at, you know, home as well."

Digital & Clinical Technology

• Digital revenue scale: Digital contributed about ₹710 crores, or 23% of overall revenue, in Q1. Sahyadri's digital maturity is yet to mature completely, and out-of-hospital care revenue opportunities are expected to start folding into that brand.
• Clinical technology additions: A linear accelerator and PET-CT were installed at Nashik; optical coherence tomography was introduced at MHB Old Airport Road, Bangalore, and two other city locations; an AI-assisted neuro biplane cath lab was commissioned in Mukundapur, Kolkata; and an interventional radiology program was launched in Kolkata.
• Clinical milestones: The quarter included the world's first robotic pancreatic surgery on a 1-month-old infant at Whitefield, Bangalore; Andhra Pradesh's first emergency living-donor liver transplant at Vijayawada; and first robotic renal transplants at the Kanakapura and Yelahanka greenfield facilities.

Strategic Boundaries

• No medical colleges in the listed entity: Management was explicit that Manipal Health Enterprises will remain focused on tertiary and quaternary care brick-and-mortar hospitals and will not dilute that focus by bringing medical colleges into the listed entity.
• Growth philosophy anchored on volumes: The stated Manipal philosophy is to serve more patients rather than pursue price-led growth, a stance management reinforced as sustainable and core to the model.

Dilip Jose: "We believe Manipal Health Enterprises should remain focused on providing the highest end of tertiary and quaternary care, the brick-and-mortar hospitals that we run. ... we would not want to dilute that focus."

Guidance & Commitments

Key Metrics